Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Avatrombopag Versus Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia: a Multicenter, Open-label, Randomized Controlled Study

NCT07278908 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07278908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07278908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Avatrombopag Versus Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia: a Multicenter, Open-label, Randomized Controlled Study
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
December 31, 2025
Completion date
December 31, 2028
Enrollment
248 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

itp - immune thrombocytopenia